Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
The partnership between Valneva and the UK government could produce the first COVID vaccine approval based on immunogenicity data.
Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.
Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.
Coronavirus Notebook: UK Seven-Vaccine Booster Trial Begins, Australia Plans mRNA Production Capacity
The company manufacturing Russia's Sputnik V vaccine in Brazil has produced the first batch, but has withdrawn a request to run clinical trials there. France is preparing to immunize the over-18s, and Australia has begun evaluating Vir/GSK’s sotrovimab for use in COVID-19 patients.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis